Brodalumab NEW

Price	$155	$397	$582
Package	1mg	5mg	10mg

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-19

Product Details

Product Name: Brodalumab	CAS No.: 1174395-19-7
Purity: 98.4% (SEC-HPLC)	Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

Name	Brodalumab
Description	Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.
In vitro	Brodalumab (AMG 827) blocks the biological activity of the IL-17A, IL-17F, and IL-17A/F heterodimer signaling pathways by binding to the IL-17RA/RC complex. Additionally, it inhibits the biological activity of the IL-25 (IL-17E) signaling pathway by binding to the IL-17RA/RB complex[1]. Brodalumab is capable of suppressing the inflammatory processes associated with psoriasis[1].
Storage	store at low temperature \| store at -20°C \| Shipping with blue ice.
Inhibitors Related	Inosine pranobex \| Apilimod mesylate \| Amlexanox \| Dexamethasone acetate \| Bornyl acetate \| L-Arginine \| Bergenin \| Dexamethasone \| α-Terpineol \| Diallyl disulfide \| Linalool \| Apilimod

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.